Loading…
Employees: 2,067
Size Wuhan Huakang Century Clean Technology (301235.SZ) is a China Health Care company (Medical Specialties) with a market value of $603M, the 3406th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥29.59 on 6 Nov 2026.
Performance Over six months the shares fell 41.5%, against -13.5% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 28.1% over the last twelve months (peer median +9.3%); the operating margin is 6.5% (peer median 8.5%).
Valuation It trades at 22.6× forward earnings against a peer median of 23.5× (6th cheapest of 11).
Capital Return on invested capital runs 5.4 points below its cost of capital (10.4% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.63B | CN¥2.28B | CN¥1.70B | CN¥1.60B | CN¥1.18B |
| Revenue growth | — | +34% | +6% | +35% | — |
| Gross profit | CN¥813M | CN¥706M | CN¥547M | CN¥575M | CN¥436M |
| EBITDA | n/a | CN¥224M | CN¥136M | CN¥145M | CN¥120M |
| Net income | CN¥108M | CN¥118M | CN¥66.8M | CN¥107M | CN¥102M |
| Free cash flow | -CN¥409M | -CN¥155M | CN¥35.8M | -CN¥723M | -CN¥464M |
| Capital expenditure | CN¥52.9M | CN¥59.3M | CN¥112M | CN¥547M | CN¥125M |
| Total debt | CN¥671M | CN¥894M | CN¥1.24B | CN¥501M | CN¥17.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301235.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.5% | -3.3% | lowest of 20 |
| 6-month return | -41.5% | -13.5% | 2nd lowest of 20 |
| Distance from 52-week high | -63.8% | -34.3% | 3rd lowest of 20 |
| Revenue growth (TTM) | +28.1% | +9.3% | highest of 20 |
| Operating margin | 6.5% | 8.5% | 9th lowest of 20 |
| Forward P/E | 22.6× | 23.5× | 6th cheapest of 11 |
| ROIC minus cost of capital | -5.4 pp | +0.4 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 90.3× | 34.4% | +6.7% |
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |